Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features

키워드

참고문헌 (127)

1. Harbord M, "The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease", J Crohns Colitis, 10, pp.239~254 (2016)[DOI]
2. Smith MP, "Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases", Am J Surg, 110, pp.239~246 (1965)[DOI]
3. Rossi RE, "Primary sclerosing cholangitis associated with inflammatory bowel disease: an update", Eur J Gastroenterol Hepatol, 28, pp.123~131 (2016)
4. Boberg KM, "Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population", Scand J Gastroenterol, 33, pp.99~103 (1998)[DOI]
5. Molodecky NA, "Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis", Hepatology, 53, pp.1590~1599 (2011)[DOI]
6. de Vries AB, "Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis", World J Gastroenterol, 21, pp.1956~1971 (2015)[DOI]
7. Tanaka A, "Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis", Liver Int, 28, pp.983~989 (2008)[DOI]
8. Shorbagi A, "Primary sclerosing cholangitis: what is the difference between east and west?", World J Gastroenterol, 14, pp.3974~3981 (2008)[DOI]
9. Sano H, "Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis", J Hepatobiliary Pancreat Sci, 18, pp.154~161 (2011)[DOI]
10. Schaeffer DF, "The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis", Dig Dis Sci, 58, pp.2608~2614 (2013)[DOI]
11. Nakazawa T, "Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?", World J Gastroenterol, 20, pp.3245~3254 (2014)[DOI]
12. Jorgensen KK, "Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients", Inflamm Bowel Dis, 18, pp.536~545 (2012)[DOI]
13. Sinakos E, "Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship", Inflamm Bowel Dis, 19, pp.1004~1009 (2013)[DOI]
14. Rojas-Feria M, "Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver", World J Gastroenterol, 19, pp.7327~7340 (2013)[DOI]
15. Loftus EV Jr, "PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis", Gut, 54, pp.91~96 (2005)[DOI]
16. Jostins L, "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease", Nature, 491, pp.119~124 (2012)[DOI]
17. Huang C, "Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans", Gastroenterology, 149, pp.1575~1586 (2015)[DOI]
18. Henriksen EK, "Update on primary sclerosing cholangitis genetics", Curr Opin Gastroenterol, 30, pp.310~319 (2014)[DOI]
19. Liu JZ, "Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis", Nat Genet, 45, pp.670~675 (2013)[DOI]
20. Tsaitas C, "Update on inflammatory bowel disease in patients with primary sclerosing cholangitis", World J Hepatol, 6, pp.178~187 (2014)[DOI]
21. Grant AJ, "Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease", Lancet, 359, pp.150~157 (2002)[DOI]
22. Adams DH, "Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease", Nat Rev Immunol, 6, pp.244~251 (2006)[DOI]
23. Eksteen B, "Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis", J Exp Med, 200, pp.1511~1517 (2004)[DOI]
24. Cesaro C, "Gut microbiota and probiotics in chronic liver diseases", Dig Liver Dis, 43, pp.431~438 (2011)[DOI]
25. Tabibian JH, "The enteric microbiome in hepatobiliary health and disease", Liver Int, 36, pp.480~487 (2016)[DOI]
26. Torres J, "Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease", Aliment Pharmacol Ther, 34, pp.497~508 (2011)[DOI]
27. Duboc H, "Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases", Gut, 62, pp.531~539 (2013)[DOI]
28. Quraishi MN, "The gut-adherent microbiota of PSC-IBD is distinct to that of IBD", Gut, 66, pp.386~388 (2017)
29. Kummen M, "The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls", Gut, 66, pp.611~619 (2017)[DOI]
30. Tabibian JH, "Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis", Hepatology, 63, pp.185~196 (2016)[DOI]
31. Joo M, "Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study", Am J Surg Pathol, 33, pp.854~862 (2009)[DOI]
32. Olsson R, "Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis", Gastroenterology, 100, pp.1319~1323 (1991)[DOI]
33. Sokol H, "Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis", World J Gastroenterol, 14, pp.3497~3503 (2008)[DOI]
34. Ye BD, "Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea", Inflamm Bowel Dis, 17, pp.1901~1906 (2011)[DOI]
35. Marelli L, "Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?", Gut, 60, pp.1224~1228 (2011)[DOI]
36. O'Toole A, "Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease", Clin Gastroenterol Hepatol, 10, pp.439~441 (2012)[DOI]
37. Boonstra K, "Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease", Inflamm Bowel Dis, 18, pp.2270~2276 (2012)[DOI]
38. Gelley F, "Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience", Transplant Proc, 44, pp.2164~2165 (2012)[DOI]
39. Halliday JS, "A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease", J Crohns Colitis, 6, pp.174~181 (2012)[DOI]
40. Singh S, "Primary sclerosing cholangitis: diagnosis, prognosis, and management", Clin Gastroenterol Hepatol, 11, pp.898~907 (2013)[DOI]
41. Moncrief KJ, "The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation: a single-centre experience", Can J Gastroenterol, 24, pp.40~46 (2010)[DOI]
42. Verdonk RC, "Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease", Am J Transplant, 6, pp.1422~1429 (2006)[DOI]
43. Haagsma EB, "Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens", Aliment Pharmacol Ther, 18, pp.33~44 (2003)[DOI]
44. Verdonk RC, "Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients", Inflamm Bowel Dis, 13, pp.703~709 (2007)[DOI]
45. Mathis KL, "Short- and long-term surgical outcomes in patients undergoing proctocolectomy with ileal pouch-anal anastomosis in the setting of primary sclerosing cholangitis", Dis Colon Rectum, 54, pp.787~792 (2011)[DOI]
46. Rabinovitz M, "Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects", Hepatology, 11, pp.7~11 (1990)[DOI]
47. Navaneethan U, "The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis", Aliment Pharmacol Ther, 35, pp.1045~1053 (2012)
48. Yanai H, "Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel Disease", J Crohns Colitis, 9, pp.177~184 (2015)[DOI]
49. Broome U, "Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis", Gut, 38, pp.610~615 (1996)[DOI]
50. Ludwig J, "Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis", Hepatology, 1, pp.632~640 (1981)[DOI]
51. Ngu JH, "Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis", Clin Gastroenterol Hepatol, 9, pp.1092~1097 (2011)[DOI]
52. Rasmussen HH, "Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease", Scand J Gastroenterol, 32, pp.604~610 (1997)[DOI]
53. Fevery J, "Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD", Aliment Pharmacol Ther, 43, pp.612~620 (2016)[DOI]
54. Singh S, "Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis", Am J Gastroenterol, 108, pp.1417~1425 (2013)[DOI]
55. Gautam M, "Recurrence of autoimmune liver disease after liver transplantation: a systematic review", Liver Transpl, 12, pp.1813~1824 (2006)[DOI]
56. van de Vrie W, "Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis", Eur J Gastroenterol Hepatol, 15, pp.657~663 (2003)[DOI]
57. Mosli M, "The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease", Gastroenterol Hepatol (N Y), 9, pp.434~441 (2013)
58. Cholongitas E, "Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation", Liver Transpl, 14, pp.138~143 (2008)
59. Alabraba E, "A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts", Liver Transpl, 15, pp.330~340 (2009)[DOI]
60. Joshi D, "The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis", Liver Int, 33, pp.53~61 (2013)[DOI]
61. Fucini C, "Bleeding from peristomal varices: perspectives on prevention and treatment", Dis Colon Rectum, 34, pp.1073~1078 (1991)[DOI]
62. Graziadei IW, "Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis", Hepatology, 30, pp.1121~1127 (1999)[DOI]
63. Narumi S, "Liver transplantation for sclerosing cholangitis", Hepatology, 22, pp.451~457 (1995)[DOI]
64. Miki C, "Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation", Br J Surg, 82, pp.1114~1147 (1995)[DOI]
65. Broome U, "Primary sclerosing cholangitis in ulcerative colitis: a risk factor for the development of dysplasia and DNA aneuploidy?", Gastroenterology, 102, pp.1877~1880 (1992)[DOI]
66. D'Haens GR, "Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis", Am J Gastroenterol, 88, pp.1174~1178 (1993)
67. Kornfeld D, "Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study", Gut, 41, pp.522~525 (1997)[DOI]
68. Kaplan GG, "Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis", Inflamm Bowel Dis, 13, pp.1401~1407 (2007)[DOI]
69. Broome U, "Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential", Hepatology, 22, pp.1404~1408 (1995)
70. Brentnall TA, "Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis", Gastroenterology, 110, pp.331~338 (1996)[DOI]
71. Leidenius MH, "Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis", Scand J Gastroenterol, 32, pp.706~711 (1997)[DOI]
72. Marchesa P, "The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis", Am J Gastroenterol, 92, pp.1285~1288 (1997)
73. Shetty K, "The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis", Am J Gastroenterol, 94, pp.1643~1649 (1999)[DOI]
74. Jess T, "Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota", Am J Gastroenterol, 102, pp.829~836 (2007)[DOI]
75. Terg R, "Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies: a large prospective study", Acta Gastroenterol Latinoam, 38, pp.26~33 (2008)
76. Lindstrom L, "Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis", Dis Colon Rectum, 54, pp.1392~1397 (2011)[DOI]
77. Ananthakrishnan AN, "Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease", J Crohns Colitis, 8, pp.956~963 (2014)[DOI]
78. Navaneethan U, "Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease", Gastroenterol Rep (Oxf), 4, pp.43~49 (2016)
79. Choi PM, "Relationship between colorectal neoplasia and primary sclerosing cholangitis in ulcerative colitis", Gastroenterology, 103, pp.1707~1709 (1992)
80. Gurbuz AK, "Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis", Dis Colon Rectum, 38, pp.37~41 (1995)[DOI]
81. Loftus EV Jr, "Risk of colorectal neoplasia in patients with primary sclerosing cholangitis", Gastroenterology, 110, pp.432~440 (1996)[DOI]
82. Nuako KW, "Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study", Cancer, 82, pp.822~826 (1998)[DOI]
83. Aitola P, "Liver involvement in patients operated for ulcerative colitis, with special reference to the association of cholangitis with colorectal dysplasia and carcinoma", Int J Colorectal Dis, 15, pp.167~171 (2000)[DOI]
84. Zheng HH, "Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies", Eur J Gastroenterol Hepatol, 28, pp.383~390 (2016)
85. Bergquist A, "Hepatic and extrahepatic malignancies in primary sclerosing cholangitis", J Hepatol, 36, pp.321~327 (2002)[DOI]
86. Brackmann S, "Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease", Scand J Gastroenterol, 44, pp.46~55 (2009)[DOI]
87. Lindberg BU, "Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study", Dis Colon Rectum, 44, pp.77~85 (2001)[DOI]
88. Broome U, "Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis", Dis Colon Rectum, 38, pp.1301~1305 (1995)[DOI]
89. Navaneethan U, "Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis", Gastrointest Endosc, 75, pp.1045~1054 (2012)[DOI]
90. Singh S, "Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis", Liver Transpl, 19, pp.1361~1369 (2013)[DOI]
91. Claessen MM, "More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis", Inflamm Bowel Dis, 15, pp.1331~1336 (2009)[DOI]
92. Thackeray EW, "Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis", Clin Gastroenterol Hepatol, 9, pp.52~56 (2011)[DOI]
93. Rudolph G, "In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival", J Hepatol, 53, pp.313~317 (2010)[DOI]
94. Hill MJ, "Bile flow and colon cancer", Mutat Res, 238, pp.313~320 (1990)[DOI]
95. Bernstein C, "Carcinogenicity of deoxycholate, a secondary bile acid", Arch Toxicol, 85, pp.863~871 (2011)[DOI]
96. colonic tumorigenesis in the rat fed deoxycholic acid, "Cancer Lett", 1999, 115~120, 10.1016[DOI]
97. Hruz P, "Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis", Gut, 55, pp.395~402 (2006)[DOI]
98. Sauer P, "Downregulation of ileal bile acid absorption in bile-duct-ligated rats", J Hepatol, 33, pp.2~8 (2000)[DOI]
99. Tlaskalova-Hogenova H, "The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases", Cell Mol Immunol, 8, pp.110~120 (2011)[DOI]
100. Sellon RK, "Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice", Infect Immun, 66, pp.5224~5231 (1998)
101. Lai KK, "Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia", Inflamm Bowel Dis, 21, pp.378~384 (2015)[DOI]
102. Begley M, "The interaction between bacteria and bile", FEMS Microbiol Rev, 29, pp.625~651 (2005)[DOI]
103. Modica S, "Nuclear bile acid receptor FXR protects against intestinal tumorigenesis", Cancer Res, 68, pp.9589~9594 (2008)[DOI]
104. Vavassori P, "The bile acid receptor FXR is a modulator of intestinal innate immunity", J Immunol, 183, pp.6251~6261 (2009)[DOI]
105. Venkatesh PG, "Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis", J Crohns Colitis, 7, pp.968~973 (2013)[DOI]
106. Wiesner RH, "Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease", Best Pract Res Clin Gastroenterol, 15, pp.667~680 (2001)[DOI]
107. Dvorchik I, "Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis", Hepatology, 35, pp.380~384 (2002)[DOI]
108. Hanouneh IA, "Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis", Inflamm Bowel Dis, 18, pp.269~274 (2012)[DOI]
109. Loftus EV Jr, "Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation", Hepatology, 27, pp.685~690 (1998)[DOI]
110. Vera A, "Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis", Transplantation, 75, pp.1983~1988 (2003)[DOI]
111. Eaton JE, "The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation", Aliment Pharmacol Ther, 38, pp.977~987 (2013)[DOI]
112. Gullberg K, "Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis", Gastroenterology, 112, pp.1487~1492 (1997)[DOI]
113. Stahlberg D, "Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study", Dis Colon Rectum, 46, pp.770~778 (2003)[DOI]
114. Imam MH, "Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis", J Crohns Colitis, 8, pp.1294~1299 (2014)[DOI]
115. Rahman M, "The clinical impact of primary sclerosing cholangitis in patients with an ileal pouch-anal anastomosis for ulcerative colitis", Int J Colorectal Dis, 26, pp.553~559 (2011)[DOI]
116. Farraye FA, "AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease", Gastroenterology, 138, pp.738~745 (2010)[DOI]
117. Biancone L, "European evidence-based consensus on the management of ulcerative colitis: special situations", J Crohns Colitis, 2, pp.63~92 (2008)[DOI]
118. Batta AK, "Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps", Cancer Res, 58, pp.1684~1687 (1998)
119. Tung BY, "Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis", Ann Intern Med, 134, pp.89~95 (2001)[DOI]
120. Pardi DS, "Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis", Gastroenterology, 124, pp.889~893 (2003)[DOI]
121. Wolf JM, "The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis", Aliment Pharmacol Ther, 22, pp.783~788 (2005)[DOI]
122. Lindstrom L, "High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia", Aliment Pharmacol Ther, 35, pp.451~457 (2012)[DOI]
123. Rudolph G, "In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment", Dig Dis Sci, 56, pp.3624~3630 (2011)[DOI]
124. Singh S, "Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis", Inflamm Bowel Dis, 19, pp.1631~1638 (2013)[DOI]
125. Gulamhusein AF, "Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD", Am J Gastroenterol, 111, pp.705~711 (2016)[DOI]
126. Burak K, "Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis", Am J Gastroenterol, 99, pp.523~526 (2004)[DOI]
127. Fevery J, "Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study", Liver Int, 32, pp.214~222 (2012)[DOI]

관련 논문AI추천